Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
复制标题
DOI：
10.1097/igc.0000000000000361
复制
发表时间：
2015-03
期刊：
影响因子：
--
通讯作者：
Blagden SP
中科院分区：
文献类型：
--
作者：
Rizzuto I;Stavraka C;Chatterjee J;Borley J;Hopkins TG;Gabra H;Ghaem-Maghami S;Huson L;Blagden SP
本研究的目的是建立一个预测卵巢癌（OC）完成一线治疗的妇女复发风险的预后指标。对2000年至2010年的OC病例数据库进行查询，包括国际妇产科联合会的分期、肿瘤分级和组织学亚型、术前和治疗后CA-125水平、细胞减缩手术后残留病变的存在或不存在、化疗后计算机断层扫描、进展和死亡时间。最强的复发预测因子被纳入一个算法，卵巢癌复发风险（ROVAR）评分。对354例OC进行分析，得出ROVAR评分。选择的因素包括术前血清CA-125，国际妇产科联合会癌症分期和分级，以及治疗后计算机断层扫描是否存在残留疾病。在验证数据集中，ROVAR评分的敏感性和特异性分别为94%和61%。验证数据集的一致性指数为0.91（95%可信区间为0.85 ~ 0.96）。该评分将患者分为低（<0.33）、中（0.34-0.67）和高（>0.67）复发概率。ROVAR评分根据一线治疗后复发的风险对患者进行分层。这可以广泛地促进治疗后护理和支持的适当定制。
The aim of this study was to construct a prognostic index that predicts risk of relapse in women who have completed first-line treatment for ovarian cancer (OC). A database of OC cases from 2000 to 2010 was interrogated for International Federation of Gynecology and Obstetrics stage, grade and histological subtype of cancer, preoperative and posttreatment CA-125 level, presence or absence of residual disease after cytoreductive surgery and on postchemotherapy computed tomography scan, and time to progression and death. The strongest predictors of relapse were included into an algorithm, the Risk of Ovarian Cancer Relapse (ROVAR) score. Three hundred fifty-four cases of OC were analyzed to generate the ROVAR score. Factors selected were preoperative serum CA-125, International Federation of Gynecology and Obstetrics stage and grade of cancer, and presence of residual disease at posttreatment computed tomography scan. In the validation data set, the ROVAR score had a sensitivity and specificity of 94% and 61%, respectively. The concordance index for the validation data set was 0.91 (95% confidence interval, 0.85-0.96). The score allows patient stratification into low (<0.33), intermediate (0.34–0.67), and high (>0.67) probability of relapse. The ROVAR score stratifies patients according to their risk of relapse following first-line treatment for OC. This can broadly facilitate the appropriate tailoring of posttreatment care and support.